Full Text

Turn on search term navigation

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Most deep-learning algorithms that use Hematoxylin- and Eosin-stained whole slide images (WSIs) to predict cancer survival incorporate image patches either with the highest scores or a combination of both the highest and lowest scores. In this study, we hypothesize that incorporating wholistic patch information can predict colorectal cancer (CRC) cancer survival more accurately. As such, we developed a distribution-based multiple-instance survival learning algorithm (DeepDisMISL) to validate this hypothesis on two large international CRC WSIs datasets called MCO CRC and TCGA COAD-READ. Our results suggest that combining patches that are scored based on percentile distributions together with the patches that are scored as highest and lowest drastically improves the performance of CRC survival prediction. Including multiple neighborhood instances around each selected distribution location (e.g., percentiles) could further improve the prediction. DeepDisMISL demonstrated superior predictive ability compared to other recently published, state-of-the-art algorithms. Furthermore, DeepDisMISL is interpretable and can assist clinicians in understanding the relationship between cancer morphological phenotypes and a patient’s cancer survival risk.

Details

Title
Colorectal Cancer Survival Prediction Using Deep Distribution Based Multiple-Instance Learning
Author
Li, Xingyu 1 ; Jonnagaddala, Jitendra 2   VIAFID ORCID Logo  ; Cen, Min 1 ; Zhang, Hong 1   VIAFID ORCID Logo  ; Xu, Steven 3   VIAFID ORCID Logo 

 School of Management, University of Science and Technology of China, Hefei 230026, China 
 School of Population Health, University of New South Wales, Sydney, NSW 2052, Australia 
 Clinical Pharmacology and Quantitative Science, Genmab US, Inc., Princeton, NJ 08540, USA 
First page
1669
Publication year
2022
Publication date
2022
Publisher
MDPI AG
e-ISSN
10994300
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2748275544
Copyright
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.